

## Medical Coverage Policy | Glucose Monitoring-Continuous



**EFFECTIVE DATE:** 01|01|2017

**POLICY LAST UPDATED:** 08|07|2018

### OVERVIEW

This policy addresses coverage of continuous (also called long-term) and short-term (also known as intermittent, monitoring for up to 72 hours) glucose monitoring.

Home blood glucose monitors are not addressed in this policy. Please see the Related Policies Section.

### MEDICAL CRITERIA

Not applicable

### PRIOR AUTHORIZATION

#### BlueCHiP for Medicare and Commercial Products

Not applicable

### POLICY STATEMENT

#### BlueCHiP for Medicare

Continuous glucose monitoring (CGM) devices defined as “therapeutic” CGMs are covered.

NOTE: Therapeutic CGMs provide information that can be used to make diabetes treatment decisions, such as changing one’s diet or insulin dosage, based solely on the readings of the CGM. They are intended to replace information obtained from blood glucose monitors.

CGMs that are used as adjunctive devices to complement, not replace, information obtained from a separate blood glucose monitor are referred to as "non-therapeutic" CGMs, and are therefore not covered.

#### Commercial Products

The use of continuous glucose monitoring is a covered service.

#### BlueCHiP for Medicare and Commercial Products

The following are not covered:

- Alcohol or peroxide (A4244, A4245), betadine or phisoHex (A4246, A4247) are not covered since these items are not required for the proper functioning of the device.
- Urine test reagent strips or tablets (A4250) are not covered since they are not used with a glucose monitor.
- Reflectance colorimeter devices used for measuring blood glucose levels in clinical settings are not covered as durable medical equipment for use in the home because their need for frequent professional re-calibration makes them unsuitable for home use.
- Glucose monitors that are not designed for use in the home must be coded A9270 and will be denied as statutorily not covered (no benefit category).
- Home blood glucose disposable monitor, including test strips (A9275) is not covered because these monitors do not meet the definition of DME.

Diabetic equipment and supplies are provided in accordance with Rhode Island General Law §27-20-30. The details of the law can be found in the *Diabetes Self-Management Education Mandate* policy.

## COVERAGE

Benefits may vary by groups/contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable office visit benefits/coverage, Diagnostic Imaging, Lab, and Machine Tests benefits/coverage, Medical Equipment, Medical Supplies and Prosthetic Devices benefits/coverage and Diabetic equipment/supplies benefits/coverage.

## BACKGROUND

The advent of blood glucose monitors for use by patients in the home revolutionized the management of diabetes. Using fingersticks, patients can monitor their blood glucose levels both to determine the adequacy of hyperglycemia control and to evaluate hypoglycemic episodes. Tight glucose control, defined as a strategy involving frequent glucose checks and a target hemoglobin A1c (HbA1c) level in the range of 7%, is now considered standard of care for diabetic patients.

Tight glucose control requires multiple daily measurements of blood glucose (ie, before meals and at bedtime), a commitment that some patients may be unwilling or unable to meet. Also, the goal of tight glucose control has to be balanced with an associated risk of hypoglycemia. Hypoglycemia is known to be a risk in patients with type 1 diabetes. While patients with insulin-treated type 2 diabetes may also experience severe hypoglycemic episodes, there is a lower relative likelihood of severe hypoglycemia compared with patients who had type 1 diabetes. An additional limitation of periodic self-measurements of blood glucose is that glucose levels are seen in isolation, and trends in glucose levels are undetected. For example, while a diabetic patient's fasting blood glucose level might be within normal values, hyperglycemia might be undetected postprandially, leading to elevated HbA1c values.

## Management

Recently, measurements of glucose in the interstitial fluid have been developed as a technique to measure glucose values automatically throughout the day, producing data that show the trends in glucose levels. Although devices measure glucose in the interstitial fluid on a periodic rather than a continuous basis, this type of monitoring is referred to as continuous glucose monitoring.

Several devices have received approval from the U.S. Food and Drug Administration (FDA). The first approved devices were the Continuous Glucose Monitoring System (MiniMed), which uses an implanted temporary sensor in the subcutaneous tissues, and the GlucoWatch G2 Biographer, an external device worn like a wristwatch that measures glucose in interstitial fluid extracted through the skin by electric current (referred to as reverse iontophoresis).

Devices subsequently approved include those for pediatric use and those with more advanced software, more frequent measurements of glucose levels, or more sophisticated alarm systems. Devices initially measured interstitial glucose every 5 to 10 minutes and stored data for download and retrospective evaluation by a clinician. With currently available devices, the intervals at which interstitial glucose is measured ranges from every 1 to 2 minutes to 5 minutes, and most provide measurements in real-time directly to patients. While CGM potentially eliminates or decreases the number of required daily fingersticks, it should be noted that, according to the FDA labeling, monitors are not intended as an alternative to traditional self-monitoring of blood glucose levels but rather as adjuncts to monitoring, supplying additional information on glucose trends not available from self-monitoring. Also, devices may be used intermittently (ie, for periods of 72 hours) or continuously (ie, on a long-term basis).

Several continuous glucose monitoring systems have been approved by FDA through the premarket approval process:

- The Continuous Glucose Monitoring System (CGMS®) (MiniMed) in 1999 (approved for 3-day use in a physician's office).
- The GlucoWatch G2® Biographer in 2001. Of note, the GlucoWatch has not been available since 2008.
- The Guardian®-RT (Real-Time) CGMS (MiniMed, now Medtronic) in ~~July~~ 2005.
- The Dexcom® STS CGMS system (DexCom) was approved by FDA in 2006.
- The Paradigm® REAL-Time System (MiniMed, now Medtronic) was approved by FDA in 2006. This system integrates a CGM with a Paradigm insulin pump. The second generation integrated system is called the MiniMed Paradigm Revel System.
- The FreeStyle Navigator® CGM System (Abbott) was approved in 2008.
- The Dexcom G4 Platinum (Dexcom) CGM was approved for use in adults 18 years and older in ~~October~~ 2012. The device can be worn for up to 7 days. In 2014, FDA expanded use to include patients with diabetes, age 2 to 17 years old.
- The Dexcom G5 Mobile CGM (Dexcom) was approved in 2016 as a replacement for fingerstick blood glucose testing in patients 2 years and older. System requires at least 2 daily fingerstick tests for calibration purposes, but additional fingersticks are not necessary because treatment decisions can be made based on device readings.
- The Freestyle Libre® Pro Flash Glucose Monitoring System (Abbott) was approved in 2017 for use in adults 18 years and older. Readings are only made available to patients through consultation with a health care professional. The system does not require user calibration with blood glucose values.

### **Blue CHiP for Medicare**

Effective for claims with dates of service on or after January 12, 2017, Medicare covers therapeutic CGM devices under the DME benefit. CGM devices covered by Medicare are defined in CMS Ruling 1682R as therapeutic CGM. CGM devices that do not meet the definition of a therapeutic CGM as defined in CMS Ruling 1682R will be denied as non-covered (no benefit).

#### **CMS Ruling 1682R**

Medicare does not cover CGMs approved by the FDA for use as adjunctive devices to complement, not replace, information obtained from blood glucose monitors. Such devices are not used for making diabetes treatment decisions, such as changing one's diet or insulin dosage based solely on the readings of the CGM, and therefore, have not been covered under Medicare because they are not considered to serve the medical purpose of making diabetes treatment decisions.

All CGMs that are for use as adjunctive devices to complement, not replace, information obtained from blood glucose monitors in making diabetes treatment decisions are referred to as "non-therapeutic" CGMs.

Therapeutic CGMs provide information that can be used to make diabetes treatment decisions, such as changing one's diet or insulin dosage, based solely on the readings of the CGM. They are intended to replace information obtained from blood glucose monitors. Therefore, claims for BGM and related supplies, billed *in addition to an approved therapeutic CGM device*, and associated supply allowance will be denied as not covered.

### **BlueCHiP for Medicare and Commercial Products**

Insulin-treated means that the member is receiving insulin injections to treat their diabetes. Insulin does not exist in an oral form and therefore members taking oral medication to treat their diabetes are not insulin treated.

Blue Cross Blue Shield of Rhode Island follows the Centers for Medicare and Medicaid Services (CMS) Medically Unlikely Edits (MUEs) regarding the number of test strips and lancets that are covered. Per CMS, the quantity of test strips (code A4253) and lancets (code A4259) that are covered depends on the usual

medical needs of the member and whether or not the member is being treated with insulin. Coverage of testing supplies is based on the following guidelines:

Usual utilization for a member who is not currently being treated with insulin injections can be up to 100 test strips and up to 100 lancets every 3 months.

Usual utilization for a member who is currently being treated with insulin injections can be up to 300 test strips and up to 300 lancets every 3 months.

## **CODING**

### **Modifiers:**

Claims for equipment and supplies should be submitted with the KX modifier for insulin dependent members.

Claims for equipment and supplies should be submitted with the KS modifier for non-insulin dependent members.

### **BlueCHiP for Medicare**

The following HCPCS codes are covered:

**K0553** Supply allowance for therapeutic continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service

**K0554** Receiver (monitor), dedicated, for use with therapeutic continuous glucose monitor system

The following HCPCS codes are not covered, as they fail to meet the definition of “therapeutic” according to CMS. Additionally, codes A9276 and A9277 are not used to bill for supplies used with code K0554.

**A9276** Sensor; invasive (e.g. subcutaneous) disposable, for use with interstitial continuous glucose monitoring system, 1 unit = 1 day supply

**A9277** Transmitter; external, for use with interstitial continuous glucose monitoring system

**A9278** Receiver (monitor); external, for use with interstitial continuous glucose monitoring system

**S1030** Continuous non-invasive glucose monitoring device, purchase (for physician interpretation of data, use CPT code)

**S1031** Continuous non-invasive glucose monitoring device, rental, including sensor, sensor replacement, and download to monitor (for physician interpretation of data, use CPT code)

### **Commercial Products**

The following HCPCS codes are covered:

**A9276** Sensor; invasive (e.g. subcutaneous) disposable, for use with interstitial continuous glucose monitoring system, 1 unit = 1 day supply

**A9277** Transmitter; external, for use with interstitial continuous glucose monitoring system

**A9278** Receiver (monitor); external, for use with interstitial continuous glucose monitoring system

**K0553** Supply allowance for therapeutic continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service

**K0554** Receiver (monitor), dedicated, for use with therapeutic continuous glucose monitor system

**S1030** Continuous non-invasive glucose monitoring device, purchase (for physician interpretation of data, use CPT code)

**S1031** Continuous non-invasive glucose monitoring device, rental, including sensor, sensor replacement, and download to monitor (for physician interpretation of data, use CPT code)

### **BlueCHiP for Medicare and Commercial Products**

The following codes are covered:

**95249** Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; patient-provided equipment, sensor placement, hook-up, calibration of monitor, patient training, and printout of recording (New Code Effective 1/1/2018)

**95250** Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; sensor placement, hook-up, calibration of monitor, patient training, removal of sensor, and printout of recording

**95251** Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; interpretation and report

## **RELATED POLICIES**

Artificial Pancreas Device System

Diabetes Self-Management Education Mandate

Glucose Monitoring - Home

## **PUBLISHED**

Provider Update, November 2018

Provider Update, June 2017

Provider Update, July 2016

Provider Update, November 2015

Provider Update, January 2015

## **REFERENCES**

1. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Home Blood Glucose Monitors (40.2)
2. Centers for Medicare and Medicaid Services. Local Coverage Determination (LCD) for Glucose Monitors (L33822)
3. Centers for Medicare and Medicaid Services. Local Coverage Article (LCA) for Glucose Monitor – Policy Article (A52464)
4. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. *Jama*. May 15 2002;287(19):2563-2569. PMID 12020338
5. 13. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2018. *Diabetes Care*. Jan 2018;41(Suppl 1):S137-s143. PMID 29222384
6. Pazos-Couselo M, Garcia-Lopez JM, Gonzalez-Rodriguez M, et al. High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study. *Can J Diabetes*. Oct 2015;39(5):428-433. PMID 26254702
7. Gehlout RR, Dogbey GY, Schwartz FL, et al. Hypoglycemia in type 2 diabetes--more common than you think: a continuous glucose monitoring study. *J Diabetes Sci Technol*. Sep 2015;9(5):999-1005. PMID 25917335
8. Food and Drug Administration (FDA). Summary of Safety and Effectiveness (SSE): Dexcom G5 Mobile Continuous Glucose Monitoring System. 2016; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf12/P120005S041b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120005S041b.pdf). Accessed February 26, 2018.
9. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Use of intermittent or continuous interstitial fluid glucose monitoring in patients with diabetes mellitus. TEC Assessments. 2003;Volume 18:Tab 16.

10. Floyd B, Chandra P, Hall S, et al. Comparative analysis of the efficacy of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus. *J Diabetes Sci Technol*. Sep 2012;6(5):1094-1102. PMID 23063035
11. Gandhi GY, Kovalaske M, Kudva Y, et al. Efficacy of continuous glucose monitoring in improving glycemic control and reducing hypoglycemia: a systematic review and meta-analysis of randomized trials. *J Diabetes Sci Technol*. Jul 2011;5(4):952-965. PMID 21880239
12. Langendam M, Luijf YM, Hooft L, et al. Continuous glucose monitoring systems for type 1 diabetes mellitus. *Cochrane Database Syst Rev*. Jan 18 2012;1:CD008101. PMID 22258980
13. Poolsup N, Suksomboon N, Kyaw AM. Systematic review and meta-analysis of the effectiveness of continuous glucose monitoring (CGM) on glucose control in diabetes. *Diabetol Metab Syndr*. Jul 23 2013;5(1):39. PMID 23876067
14. Wojciechowski P, Rys P, Lipowska A, et al. Efficacy and safety comparison of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes: systematic review and meta-analysis. *Pol Arch Med Wewn*. Oct 2011;121(10):333-343. PMID 22045094
15. Yeoh E, Choudhary P, Nwokolo M, et al. Interventions that restore awareness of hypoglycemia in adults with type 1 diabetes: a systematic review and meta-analysis. *Diabetes Care*. Aug 2015;38(8):1592-1609. PMID 26207053
16. Benkhadra K, Alahdab F, Tamhane S, et al. Real-time continuous glucose monitoring in type 1 diabetes: a systematic review and individual patient data meta-analysis. *Clin Endocrinol (Oxf)*. Mar 2017;86(3):354-360. PMID 27978595
17. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. *Lancet Diabetes Endocrinol*. Nov 2016;4(11):893-902. PMID 27641781
18. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. *Diabetes Care*. Jul 1994;17(7):697-703. PMID 7924780
19. Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The GOLD randomized clinical trial. *Jama*. Jan 24 2017;317(4):379-387. PMID 28118454
20. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. *Jama*. Jan 24 2017;317(4):371-378. PMID 28118453
21. Riddlesworth T, Price D, Cohen N, et al. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. *Diabetes Ther*. Aug 2017;8(4):947-951. PMID 28616804
22. Polonsky WH, Hessler D, Ruedy KJ, et al. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. *Diabetes Care*. Jun 2017;40(6):736-741. PMID 28389582



23. Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. *Lancet*. Nov 25 2017;390(10110):2347-2359. PMID 28923465
24. Newman SP, Cooke D, Casbard A, et al. A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE). *Health Technol Assess*. May 2009;13(28):iii-iv, ix-xi, 1-194. PMID 19476724
25. Voormolen DN, Devries JH, Evers IM, et al. The efficacy and effectiveness of continuous glucose monitoring during pregnancy: a systematic review. *Obstet Gynecol Surv*. Nov 2013;68(11):753-763. PMID 24193194
26. Murphy HR, Rayman G, Lewis K, et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. *BMJ*. Sep 25 2008;337:a1680. PMID 18818254
27. Secher AL, Ringholm L, Andersen HU, et al. The effect of real-time continuous glucose monitoring in pregnant women with diabetes: a randomized controlled trial. *Diabetes Care*. Jul 2013;36(7):1877-1883. PMID 23349548
28. Allen NA, Fain JA, Braun B, et al. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial. *Diabetes Res Clin Pract*. Jun 2008;80(3):371-379. PMID 18304674

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

